扶桑薬品工業の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2024/04/10 | 2,194 | 2,229 | 2,188 | 2,214 | +13 | +0.6% | 6,200 |
| 2024/04/09 | 2,177 | 2,217 | 2,177 | 2,201 | +15 | +0.7% | 8,100 |
| 2024/04/08 | 2,178 | 2,197 | 2,153 | 2,186 | +11 | +0.5% | 9,400 |
| 2024/04/05 | 2,148 | 2,177 | 2,140 | 2,175 | +11 | +0.5% | 7,900 |
| 2024/04/04 | 2,163 | 2,168 | 2,146 | 2,164 | +2 | +0.1% | 11,100 |
| 2024/04/03 | 2,126 | 2,169 | 2,126 | 2,162 | +20 | +0.9% | 14,900 |
| 2024/04/02 | 2,152 | 2,158 | 2,126 | 2,142 | -22 | -1% | 23,100 |
| 2024/04/01 | 2,201 | 2,201 | 2,164 | 2,164 | -37 | -1.7% | 12,300 |
| 2024/03/29 | 2,198 | 2,220 | 2,195 | 2,201 | +19 | +0.9% | 11,500 |
| 2024/03/28 | 2,324 | 2,324 | 2,181 | 2,182 | -176 | -7.5% | 42,600 |
| 2024/03/27 | 2,350 | 2,363 | 2,338 | 2,358 | +14 | +0.6% | 124,300 |
| 2024/03/26 | 2,309 | 2,344 | 2,309 | 2,344 | +25 | +1.1% | 16,900 |
| 2024/03/25 | 2,320 | 2,345 | 2,314 | 2,319 | -6 | -0.3% | 18,200 |
| 2024/03/22 | 2,332 | 2,342 | 2,317 | 2,325 | -7 | -0.3% | 13,300 |
| 2024/03/21 | 2,350 | 2,350 | 2,326 | 2,332 | +5 | +0.2% | 17,700 |
| 2024/03/19 | 2,317 | 2,334 | 2,303 | 2,327 | +7 | +0.3% | 28,800 |
| 2024/03/18 | 2,329 | 2,346 | 2,313 | 2,320 | ±0 | ±0% | 22,200 |
| 2024/03/15 | 2,315 | 2,339 | 2,302 | 2,320 | +5 | +0.2% | 39,800 |
| 2024/03/14 | 2,280 | 2,315 | 2,265 | 2,315 | +26 | +1.1% | 17,000 |
| 2024/03/13 | 2,285 | 2,298 | 2,260 | 2,289 | +8 | +0.4% | 16,900 |
| 2024/03/12 | 2,254 | 2,281 | 2,241 | 2,281 | +11 | +0.5% | 11,200 |
| 2024/03/11 | 2,300 | 2,300 | 2,242 | 2,270 | -48 | -2.1% | 22,700 |
| 2024/03/08 | 2,273 | 2,318 | 2,273 | 2,318 | +20 | +0.9% | 23,700 |
| 2024/03/07 | 2,300 | 2,320 | 2,290 | 2,298 | -1 | ±0% | 22,500 |
| 2024/03/06 | 2,241 | 2,299 | 2,233 | 2,299 | +57 | +2.5% | 51,900 |
| 2024/03/05 | 2,223 | 2,253 | 2,223 | 2,242 | +3 | +0.1% | 10,200 |
| 2024/03/04 | 2,245 | 2,249 | 2,221 | 2,239 | -11 | -0.5% | 14,700 |
| 2024/03/01 | 2,245 | 2,250 | 2,216 | 2,250 | -14 | -0.6% | 27,800 |
| 2024/02/29 | 2,262 | 2,285 | 2,243 | 2,264 | +3 | +0.1% | 25,200 |
| 2024/02/28 | 2,284 | 2,309 | 2,255 | 2,261 | -15 | -0.7% | 24,800 |
| 2024/02/27 | 2,255 | 2,290 | 2,255 | 2,276 | +21 | +0.9% | 20,900 |
| 2024/02/26 | 2,214 | 2,257 | 2,214 | 2,255 | +41 | +1.9% | 23,600 |
| 2024/02/22 | 2,210 | 2,222 | 2,198 | 2,214 | +4 | +0.2% | 11,300 |
| 2024/02/21 | 2,186 | 2,214 | 2,182 | 2,210 | +4 | +0.2% | 11,500 |
| 2024/02/20 | 2,212 | 2,229 | 2,199 | 2,206 | -6 | -0.3% | 19,500 |
| 2024/02/19 | 2,173 | 2,214 | 2,173 | 2,212 | +48 | +2.2% | 16,700 |
| 2024/02/16 | 2,145 | 2,173 | 2,136 | 2,164 | +19 | +0.9% | 17,100 |
| 2024/02/15 | 2,127 | 2,147 | 2,116 | 2,145 | +9 | +0.4% | 16,100 |
| 2024/02/14 | 2,166 | 2,172 | 2,116 | 2,136 | -19 | -0.9% | 25,800 |
| 2024/02/13 | 2,193 | 2,256 | 2,066 | 2,155 | -37 | -1.7% | 117,500 |
| 2024/02/09 | 2,194 | 2,208 | 2,184 | 2,192 | -9 | -0.4% | 12,400 |
| 2024/02/08 | 2,216 | 2,216 | 2,173 | 2,201 | -11 | -0.5% | 17,700 |
| 2024/02/07 | 2,189 | 2,227 | 2,189 | 2,212 | +26 | +1.2% | 45,000 |
| 2024/02/06 | 2,175 | 2,206 | 2,159 | 2,186 | +7 | +0.3% | 39,000 |
| 2024/02/05 | 2,180 | 2,183 | 2,156 | 2,179 | -1 | ±0% | 35,100 |
| 2024/02/02 | 2,197 | 2,197 | 2,175 | 2,180 | -17 | -0.8% | 23,800 |
| 2024/02/01 | 2,190 | 2,211 | 2,187 | 2,197 | -12 | -0.5% | 15,900 |
| 2024/01/31 | 2,194 | 2,209 | 2,176 | 2,209 | +19 | +0.9% | 14,700 |
| 2024/01/30 | 2,221 | 2,233 | 2,186 | 2,190 | -43 | -1.9% | 26,700 |
| 2024/01/29 | 2,232 | 2,255 | 2,223 | 2,233 | +11 | +0.5% | 17,400 |
251～
300
件表示中 / 3683件
類似銘柄と比較する
現在ご覧いただいている「扶桑薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 扶桑薬 | 231,400円 | +8.3% | +98.1% | 3.54% | 7.60倍 | 0.52倍 |
|
人工腎臓用透析剤・補液が主軸の製薬中堅、透析剤は国内シェア５割。後発薬や製造受託も展開 |
| ミズホメディ | 148,000円 | +1.2% | -13.9% | 5.74% | 8.73倍 | 1.62倍 |
|
体外検査薬専業、感染症抗体、遺伝子検査機器、試薬開発。新型コロナで急成長、妊娠検査薬も |
| アンジェス | 6,900円 | +110.0% | - | 0.00% | - | 11.00倍 |
|
大阪大医学部、森下竜一教授創業の創薬ベンチャー。遺伝子治療薬を核に核酸医薬など開発多彩 |
| ＣＡＮＢＡＳ | 99,100円 | - | - | 0.00% | - | 6.34倍 |
|
抗がん剤開発に特化した創薬ベンチャー。主力の膵臓がん治療薬候補は自社開発。導出も模索 |
| ステムリム | 30,400円 | - | - | 0.00% | - | 2.80倍 |
|
大阪大学発バイオベンチャー。損傷細胞の活性化物質を動員、再生を促す「再生誘導医薬」を開発 |
市場注目の銘柄
チャート関連のコラム
